Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection.
In: Vaccines, Jg. 10 (2022-09-01), Heft 9, S. 1548-1557
Online
academicJournal
Zugriff:
The emergence of the SARS-CoV-2 variants of concern has greatly influenced the immune correlates of protection, and there are little data about the antibody threshold concentrations to protect against infection with SARS-CoV-2 Omicron BA.1 or BA.2. We analyzed the antibody responses of 259 vaccinated healthcare workers, some of whom had been previously infected by SARS-CoV-2. The median follow-up was 179 days (IQR: 171–182) after blood collection. We detected 88 SARS-CoV-2 Omicron infections during the follow-up period, 55 (62.5%) with SARS-CoV-2 BA.1, and 33 (37.5%) with SARS-CoV-2 BA.2. A neutralizing antibody titer below 8 provided no protection against a BA.1 infection, a titer of 16 or 32 gave 73.2% protection, and a titer of 64 or 128 provided 78.4% protection. Conversely, the BA.2 infection rate did not vary as a function of anti-BA.2 neutralizing antibody titers. Binding antibody concentrations below 6000 BAU/mL provided no protection against Omicron BA.1 infection, 6000–20,000 BAU/mL provided 55.6% protection, and 20,000 or more provided 87.7% protection. There was no difference in BA.2 infection depending on the binding antibody concentration. Further studies are needed to investigate the relationship between antibody concentrations and infection with the Omicron BA.4/5 variants that are becoming predominant worldwide. [ABSTRACT FROM AUTHOR]
Copyright of Vaccines is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection.
|
---|---|
Autor/in / Beteiligte Person: | Dimeglio, Chloé ; Migueres, Marion ; Bouzid, Naémie ; Chapuy-Regaud, Sabine ; Gernigon, Caroline ; Da-Silva, Isabelle ; Porcheron, Marion ; Martin-Blondel, Guillaume ; Herin, Fabrice ; Izopet, Jacques |
Link: | |
Zeitschrift: | Vaccines, Jg. 10 (2022-09-01), Heft 9, S. 1548-1557 |
Veröffentlichung: | 2022 |
Medientyp: | academicJournal |
ISSN: | 2076-393X (print) |
DOI: | 10.3390/vaccines10091548 |
Schlagwort: |
|
Sonstiges: |
|